Lonza Group 1H 2026 Performance Signals A Bold Shift To Manufacturing

High Performance and a Bold Return to Core Strengths

Lonza’s 1H 2026 results have delivered a powerful signal to the market, characterized by a rare and potent combination of double-digit sales growth and significant margin expansion. The company reported a 16.0% increase in sales at constant exchange rates (CER), paired with a substantial leap in profitability across its continuing Contract Development and Manufacturing Organization (CDMO) business. This performance is anchored by a major strategic move: the Swiss Franc 2.3 billion divestiture of its “Capsules & Health Ingredients” (CHI) segment.

This strategic shedding of the CHI business marks a definitive transition. By moving away from health ingredients, Lonza is stripping back its operational complexity to emerge as a leaner, high-margin CDMO powerhouse. The momentum generated in the first half of the year has already translated into a tangible upgrade of the full-year financial outlook, suggesting that the “new” Lonza is operating with higher efficiency than previously anticipated.

For the strategist, the quality of these earnings is validated by more than just raw numbers. Lonza has secured an expansion of a strategic long-term collaboration with a leading US biopharmaceutical company and continues to invest in the future, such as the new commercial-scale ADC drug product capacity in Stein. This is a business profile increasingly geared toward high-growth, technically specialized modalities.

The 4.4 Percentage Point Margin Leap

The most striking figure in the 1H 2026 report is the CORE EBITDA margin, which reached 34.8% for the continuing CDMO business. This represents a significant 4.4 percentage point expansion over 1H 2025. This jump was primarily driven by strong operational leverage and a more favorable product mix. However, investors should also recognize the “mathematical pruning” at play; by reclassifying the lower-margin CHI business (~27%) as discontinued, Lonza has structurally elevated the Group’s margin profile.

For the investor, this expansion suggests that Lonza is successfully navigating the capital-intensive nature of biologics by improving the profitability of its underlying assets. The efficiency gains were robust enough to prompt an immediate upgrade to the full-year guidance.

Upgraded Outlook 2026: CORE EBITDA margin expected to reach a level of 33–34% (previously: above 32%) with an unchanged CER sales growth of 11–12%

Advanced Synthesis is the New Growth Engine

The Advanced Synthesis segment emerged as the standout performer of the half-year, posting an exceptionally strong CER sales growth of 27.7%. Even more impressive was the segment’s CORE EBITDA margin, which hit 48.1%. This performance was fueled by intense demand across both Small Molecules and Bioconjugates, supported by disciplined operational execution and high asset utilization.

While this performance benefited from a comparison against a low prior year base, the underlying momentum appears structural. Management noted that while margins may normalize slightly in the second half due to a shifting product mix and a tougher prior-year comparison base, the fundamental efficiency and high utilization rates in this segment remain a massive strategic win for the Group.

Shedding Weight: The Swiss Franc 2.3 Billion CHI Divestiture

A critical component of Lonza’s transformation is the agreement to sell the CHI business. By moving this segment into “Discontinued Operations,” Lonza is removing a division that, while stable, did not align with the high-growth, technically complex profile of its CDMO core.

• Buyer: Lone Star Funds
• Enterprise Value: Swiss Franc 2.3 billion
• Strategic Intent: Transitioning to a pure-play CDMO identity and simplifying corporate structure.

Specialized Modalities Finds Its Footing

Specialized Modalities returned to a strong growth trajectory, reporting 22.6% CER sales growth. Profitability improved by a massive 10.7 percentage points, reaching a 28.0% CORE EBITDA margin.

This turnaround was driven by successful customer-related plant adaptations and a return to microbial growth from a lower base. The approval of a sixth commercial therapy in Cell & Gene provides concrete proof that this technical platform is maturing toward commercial scale.

“Specialized Modalities continues to see healthy business momentum for development and commercial services, with a sixth commercial therapy approved within the Cell & Gene Technology Platform.”

Efficiency by the Numbers: 1H 2026 Segment Comparison

The following table compares the performance of Lonza’s three continuing business segments, highlighting the varying degrees of growth and profitability across the portfolio.

Strategist’s Note: Integrated Biologics remains the volume anchor of the Group, maintaining a stable 36.0% margin despite the high volatility and ramp-up costs seen in newer modalities.

ROIC and Cash Flow: The Quality of Earnings

Beyond top-line growth, the quality of Lonza’s earnings improved markedly through capital efficiency. The Return on Invested Capital (ROIC) rose to 13.2%, compared to 10.5% in the prior year. Crucially, this improvement occurred even as Lonza deployed Swiss Franc 530 million in capital expenditures (CapEx) to expand its manufacturing footprint.

Operational Free Cash Flow also showed significant improvement, delivering Swiss Franc 0.4 billion (before acquisitions and divestitures). This cash generation provides the necessary liquidity to continue investing in commercial-scale drug product capacity, ensuring that Lonza can fund its ambitious growth without over-leveraging the balance sheet.

Improving ROIC despite heavy CapEx spend confirms that Lonza’s growth is increasingly self-sustaining and capital-efficient.

A Pure-Play CDMO Future

Lonza’s 1H 2026 results represent more than just a strong half-year; they signal the successful execution of a major strategic pivot. By divesting CHI and achieving record-level margins in its core segments, the company has transformed into a specialized, high-margin entity that is deeply integrated into the global biopharmaceutical value chain.

With the CHI divestiture nearly complete and margins hitting record levels, is Lonza now the undisputed benchmark for the global CDMO industry?

Related stories: Foundation Healthcare’s IPO Breakdown